Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer
Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase...
Eli Lilly
Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio
Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...
Eli Lilly Completes Acquisition of Dice Therapeutics for $2.0 Billion
Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics...
Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials
US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...
Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute
A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly &...
Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...
Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...
Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease
Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...
Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review
US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...
Allen Institute for Immunology Partners with Eli Lilly to Study Atopic Dermatitis and Rheumatoid Arthritis
The US-based Allen Institute for Immunology has announced a strategic partnership with compatriot company Eli...
Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...
Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC
China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...
XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services
Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly &...
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the...
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...
Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE
The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...
Kelun Pharma’s Generic Jardiance Gains New Indication in China
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...
Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study
US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...
Eli Lilly Reports Q4 Financials with COVID-19 Impact and Market Performers
Eli Lilly & Co. (NYSE: LLY) reported its Q4 2022 financials, revealing a 9% year-on-year...